DK2834237T3 - Heterocyclylforbindelser som mek-inhitorer - Google Patents

Heterocyclylforbindelser som mek-inhitorer Download PDF

Info

Publication number
DK2834237T3
DK2834237T3 DK13712929.2T DK13712929T DK2834237T3 DK 2834237 T3 DK2834237 T3 DK 2834237T3 DK 13712929 T DK13712929 T DK 13712929T DK 2834237 T3 DK2834237 T3 DK 2834237T3
Authority
DK
Denmark
Prior art keywords
compound
amino
fluoro
substituted
alkyl
Prior art date
Application number
DK13712929.2T
Other languages
English (en)
Inventor
Bhavesh Dave
Rakesh Kumar Banerjee
Samiron Phukan
Abhijit Datta Khoje
Rajkumar Hangarge
Jitendra Sambhaji Jadhav
Venkata P Palle
Rajender Kumar Kamboj
Original Assignee
Lupin Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=47997632&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK2834237(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Lupin Ltd filed Critical Lupin Ltd
Application granted granted Critical
Publication of DK2834237T3 publication Critical patent/DK2834237T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/541—Non-condensed thiazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/10—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Communicable Diseases (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Cardiology (AREA)
  • Radiology & Medical Imaging (AREA)
  • Pathology (AREA)
  • Diabetes (AREA)
  • Pulmonology (AREA)
  • Hospice & Palliative Care (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Dermatology (AREA)
  • Psychiatry (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)
  • Vascular Medicine (AREA)

Claims (17)

  1. 1. Forbindelse ifølge den generelle formel I, dens tautomere form, dens stereoisomer, dets farmaceutisk acceptable salt, dens kombinationer med egnet lægemiddel og dens farmaceutiske sammensætning,
    hvor: R1 er valgt fra gruppen bestående af hydrogen, substitueret eller usubstitueret alkyl, substitueret eller usubstitueret alkenyl, substitueret eller usubstitueret alkynyl, substitueret eller usubstitueret cycloalkyl, substitueret eller usubstitueret cycloalkenyl, substitueret eller usubstitueret aryl, substitueret eller usubstitueret heteroaryl og substitueret eller usubstitueret heterocyclyl; R2 er valgt fra gruppen bestående af -(C(Rc)(Rd))m-C(=O)-N(R5)R7, -C(=O)N(R8)R9 og - O-(C(Rc)(Rd))m-C(=O)-N(R5)R7; R3 er valgt fra gruppen bestående af hydrogen, substitueret eller usubstitueret alkyl og substitueret eller usubstitueret cycloalkyl; R4 er valgt fra gruppen bestående af hydrogen, halogen, substitueret eller usubstitueret alkyl og substitueret eller usubstitueret cycloalkyl; R5 er substitueret eller usubstitueret aryl, hvor substituenterne er valgt blandt Ra og Rb; R5 og R7 er hver uafhængigt af hinanden valgt fra gruppen bestående af hydrogen, substitueret eller usubstitueret alkyl, substitueret eller usubstitueret cycloalkyl og substitueret eller usubstitueret heterocyclyl; eller R5 og R7 sammen med nitrogenet, til hvilke de er bundet, danner en substitueret eller usubstitueret heterocyklus; R8 og R9 er hver uafhængigt af hinanden valgt fra gruppen bestående af hydrogen, substitueret eller usubstitueret cycloalkyl og substitueret eller usubstitueret heterocyclyl, eller R8 og R9 sammen med nitrogenet, til hvilke de er bundet, danner en substitueret eller usubstitueret heterocyklus; med betingelserne at både R8 og R9 ikke kan være hydrogen på samme tid; og når R8 og R9 ikke er en del af en heterocyklus dannet sammen med det nitrogen til hvilket de er bundet til, er mindst én af R8 og R9 substitueret eller usubstitueret cycloalkyl eller substitueret eller usubstitueret heterocyclyl; Ra og Rb er valgt fra gruppen bestående af hydrogen, halogen og haloalkyl; Rc og Rd er uafhængigt af hinanden valgt fra gruppen bestående af hydrogen, halogen, hydroxyl og substitueret eller usubstitueret alkyl; eller Rc og Rd sammen med carbonatomet, til hvilke de er bundet, danner en substitueret eller usubstitueret cycloalkyl; m er et heltal valgt fra gruppen bestående af 1, 2, 3 og 4; yderligere, hvor: når alkylgruppen eller alkenylgruppen er substitueret, er alkylgruppen eller alkenylgruppen substitueret med 1 til 4 substituenter uafhængigt af hinanden valgt fra gruppen bestående af oxo, halogen, nitro, cyano, perhaloalkyl, cycloalkyl, aryl, heteroaryl, heterocyclyl, -OR10b, -SO2R10a, -C(=O)OR10a, - OC(=O)R10a, -C(=O)N(H)R10, -OR10a, -C(=O)N(alkyl)R10, -N(H)C(=O)R10a, -N(H)R10, - N(alkyl)R10, -N(H)C(=O)N(H)R10, - N(H)C(=O)N(alkyl)R10, -NH-SO2-alkyl og -NH-SO2-cycloalkyl; når cycloalkylgruppen eller cycloalkenylgruppen er substitueret, er cycloalkylgruppen eller cycloalkenylgruppen substitueret med 1 til 3 substituenter uafhængigt af hinanden valgt fra gruppen bestående af oxo, halogen, nitro, cyano, alkyl, alkenyl, perhaloalkyl, hydroxyalkyl, aryl, heteroaryl, heterocyclyl, -OR10b, -SO2R10a, -C(=O)R10a, -C(=O)OR10a, -OC(=O)R10a, - C(=O)N(H)R10, -C(=O)N(alkyl)R10, -N(H)C(=O)R10a, -N(H)R10, -N(alkyl)R10, -N(H)C(=O)N(H)R10, -N(H)C(=O)N(alkyl)R10, -NH-SO2-alkyl og -NH-SO2-cycloalkyl; når arylgruppen er substitueret, er arylgruppen substitueret med 1 til 3 substituenter uafhængigt af hinanden valgt fra gruppen bestående af halogen, nitro, cyano, hydroxy, alkyl, alkenyl, perhaloalkyl, cycloalkyl, cycloalkenyl, heterocyklus, -O-alkyl, -0-perhaloalkyl, - N(alkyl)alkyl, -N(H)alkyl, -NH2, -SO2-alkyl, -SO2-perhaloalkyl, N(alkyl)C(=O)alkyl, - N(H)C(=O)alkyl, -C(=O)N(alkyl)alkyl, -C(=O)N(H)alkyl, -C(=O)NH2, -SO2N(alkyl)alkyl, - SO2N(H)alkyl, -SO2NH2, -NH-SO2-alkyl og -NH-SO2-cycloalkyl; når heteroarylgruppen er substitueret, er heteroarylgruppen substitueret med 1 til 3 substituenter uafhængigt af hinanden valgt fra gruppen bestående af halogen, nitro, cyano, hydroxy, alkyl, alkenyl, perhaloalkyl, cycloalkyl, cycloalkenyl, heterocyklus, -0-alkyl, O-perhaloalkyl, -N(alkyl)alkyl, - N(H)alkyl, -NH2, -SO2-alkyl, -SO2-perhaloalkyl, -N(alkyl)C(=O)alkyl, -N(H)C(=O)alkyl, - C(=O)N(alkyl)alkyl, -C(=O)N(H)alkyl, -C(=O)NH2, -SO2N(alkyl)alkyl, -SO2N(H)alkyl, -SO2NH2, -NH-SO2-alkyl og -NH-SO2-cycloalkyl; når heterocyclylgruppen er substitueret, er heterocyclylgruppen substitueret med 1 til 3 substituenter, når den heterocykliske gruppe er substitueret på en carbonring af 'heterocyklusen', substituenterne er uafhængigt af hinanden valgt fra gruppen bestående af halogen, nitro, cyano, oxo, alkyl, alkenyl, perhaloalkyl, cycloalkyl, cycloalkenyl, aryl, heteroaryl, heterocyclyl, -OR10b, - C(=O)OR10a, -OC(=O)R10a, -C(=O)N(H)R10, C(=O)N(alkyl)R10, -N(H)C(=O)R10a, -N(H)R10, - N(alkyl)R10, -N(H)C(=O)N(H)R10, - N(H)C(=O)N(alkyl)R10; når den heterocykliske gruppe er substitueret på en nitrogenring af 'heterocyklusen', substituenterne er uafhængigt af hinanden valgt fra gruppen bestående af alkyl, alkenyl, cycloalkyl, cycloalkenyl, aryl, heteroaryl, -SO2R10a, - C(=O)R10a, C(=O)OR10a, -C(=O)N(H)R10, -C(=O)N(alkyl)R10, -NH-SO2-alkyl og -NH-SO2-cycloalkyl; når den heterocykliske gruppe er substitueret på en svovlring af 'heterocyklusen', er svovlet substitueret med 1 eller 2 oxogrupper; R10 er valgt fra gruppen bestående af hydrogen, alkyl, alkenyl, cycloalkyl, cycloalkenyl, aryl, heteroaryl og heterocyclyl; R10a er valgt fra gruppen bestående af alkyl, alkenyl, perhaloalkyl, cycloalkyl, cycloalkenyl, aryl, heteroaryl og heterocyclyl; og R10b er valgt fra gruppen bestående af hydrogen, alkyl, alkenyl, perhaloalkyl, cycloalkyl, cycloalkenyl, aryl, heteroaryl og heterocyclyl.
  2. 2. Forbindelse ifølge krav 1, hvor R1 er valgt fra gruppen bestående af hydrogen, substitueret eller usubstitueret alkyl, substitueret eller usubstitueret alkenyl, substitueret eller usubstitueret cycloalkyl og substitueret eller usubstitueret heterocyclyl.
  3. 3. Forbindelse ifølge krav 1 eller 2, hvor R3 og R4 er uafhængigt af hinanden substitueret eller usubstitueret alkyl, og/eller, hvor Ra og Rb er uafhængigt af hinanden hydrogen eller halogen, og/eller hvor Rc og Rd er uafhængigt af hinanden valgt fra gruppen bestående af hydrogen, substitueret eller usubstitueret alkyl, halogen og hydroxyl; eller Rc og Rd sammen med carbonatomet, til hvilke de er bundet, danner en substitueret eller usubstitueret cycloalkyl ring.
  4. 4. Forbindelse ifølge et hvilket som helst af kravene 1-3, hvor m er 1 eller 2.
  5. 5. Forbindelse ifølge et hvilket som helst af kravene 1-4, hvor R5 og R7 er uafhængigt af hinanden valgt fra gruppen bestående af hydrogen, substitueret eller usubstitueret alkyl, substitueret eller usubstitueret cycloalkyl og substitueret eller usubstitueret heterocyclyl; eller R5 og R7 sammen med nitrogenatomet, til hvilke de er bundet, danner en substitueret eller usubstitueret heterocyklus.
  6. 6. Forbindelse ifølge et hvilket som helst af kravene 1-5, hvor R8 og R9 er uafhængigt af hinanden valgt fra gruppen bestående af hydrogen, substitueret eller usubstitueret cycloalkyl og substitueret eller usubstitueret heterocyclyl; eller R8 og R9 sammen med nitrogenet, til hvilke de er bundet, danner en substitueret eller usubstitueret heterocyklus; med betingelsenen at både R8 og R9 ikke er hydrogen på samme tid, og når R8 og R9 ikke er en del af en heterocyklus dannet sammen med det nitrogen de er bundet til, er mindst én af R8 og R9 substitueret eller usubstitueret cycloalkyl eller substitueret eller usubstitueret heterocyclyl.
  7. 7. Forbindelse ifølge et hvilket som helst af kravene 1-6, hvor: R1 er valgt fra gruppen bestående af hydrogen, substitueret eller usubstitueret alkyl, substitueret eller usubstitueret alkenyl og substitueret eller usubstitueret heterocyclyl; R3 og R4 er uafhængigt af hinanden substitueret eller usubstitueret alkyl; Ra og Rb er uafhængigt af hinanden hydrogen eller halogen; Rc og Rd er uafhængigt af hinanden valgt fra gruppen bestående af hydrogen, substitueret eller usubstitueret al kyl, halogen og hydroxyl, eller Rc og Rd sammen med carbonatomet, til hvilke de er bundet, danner en substitueret eller usubstitueret cycloalkylring; m er 1 eller 2; R5 og R7 er uafhængigt af hinanden valgt fra gruppen bestående af hydrogen, substitueret eller usubstitueret alkyl, substitueret eller usubstitueret cycloalkyl og substitueret eller usubstitueret heterocyclyl; eller R5 og R7 sammen med nitrogenatomet, til hvilke de er bundet, danner en substitueret eller usubstitueret heterocyklus; R8 og R9 er uafhængigt af hinanden valgt fra gruppen bestående af hydrogen, substitueret eller usubstitueret cycloalkyl og substitueret eller usubstitueret heterocyclyl, eller R8 og R9 sammen med nitrogenet, til hvilke de er bundet, danner en substitueret eller usubstitueret heterocyklus; med betingelserne at både R8 og R9 ikke er hydrogen på samme tid, og når R8 og R9 ikke er en del af en heterocyklus dannet sammen med det nitrogen til hvilket de er bundet, er mindst én af R8 og R9 substitueret eller usubstitueret cycloalkyl eller substitueret eller usubstitueret heterocyclyl.
  8. 8. Forbindelse ifølge et hvilket som helst af kravene 1-7, hvor: R1 er valgt fra gruppen bestående af hydrogen, methyl, ethyl, isopropyl, allyl, difluoromethyl, cyclopropyl, 3-oxetanyl, -CH2COOC2H5, -CH2CH(OH)CH2(OH) og^FUOH; R3 og R4 er methyl; Ra og Rb er uafhængigt af hinanden hydrogen, fluor eller iod; Rc og Rd er uafhængigt af hinanden valgt fra gruppen bestående af hydrogen, methyl, fluor og hydroxyl, eller Rc og Rd sammen med carbonatomet, til hvilket de er bundet, danner en substitueret eller usubstitueret cyclopropyl; m er 1 eller 2; R5 og R7 er uafhængigt af hinanden valgt fra gruppen bestående af methyl, cyclopropyl og 3-oxetan; eller R5 og R7 sammen med nitrogenatomet, til hvilket de er bundet, danner enzetidinyl eller 3-hydroxyazetidinyl; R8 og R9 er uafhængigt af hinanden valgt fra gruppen bestående af hydrogen, cyclopropyl, cyclopropyl substitueret med -C(=O)NH2 eller -CH2OH, 3-oxetanyl, tetrahydrofuran-3-yl og tetrahydro-2H-pyranyl, eller R8 og R9 er sammen med nitrogenet som de er bundet til danner 1,1-dioxidothiazolidinyl, 1,1-dioxidothiomorpholinyl, morpholinyl, azetidinyl, 1-pyrrolidinyl, piperazinyl, 4-methylpiperazinyl, 3-hydroxypyrrolidinyl eller 4-hydroxypiperidinyl; med betingelserne, at både R8 og R9 ikke er hydrogen på samme tid, og når R8 og R9 ikke er en del af en heterocyklus dannet sammen med det nitrogen som de er bundet til, er mindst én af R8 og R9 substitueret eller usubstitueret cycloalkyl eller substitueret eller usubstitueret heterocyclyl.
  9. 9. Forbindelser ifølge et hvilket som helst af kravene 1 til 8, hvor forbindelsen er valgt fra gruppen bestående af 3-(3-(5-((2-fluor-4-iodophenyl)amino)-6,8-dimethyl-2,4,7-trioxo-3,4,6,7- tetrahydropyrido[4,3-d]pyrimidin-l(2H)-yl)phenyl)propanamid(Forbindelse-l); N-cyclopropyl-3-(5-((2-fluor-4-iodophenyl)amino)-6,8-dimethyl-2,4,7-trioxo-3,4,6,7- tetrahydropyrido[4,3-d]pyrimidin-l(2H)-yl)benzamid (Forbindelse 2); 1- (3-(azetidine-l-carbonyl)phenyl)-5-((2-fluor-4-iodophenyl)amino)-6,8-dimethylpyrido[4,3-d]pyrimidin-2,4,7(lH,3H,6H)-trion (Forbindelse-3); N-cyclopropyl-2-(3-(5-((2-fluor-4-iodophenyl)amino)-6,8-dimethyl-2,4,7-trioxo- 3.4.6.7- tetrahydropyrido[4,3-d]pyrimidin-l(2H)-yl)phenyl)acetamid (Forbindelse 4); 2- (3-(5-((2-fluor-4-iodophenyl)amino)-6,8-dimethyl-2,4,7-trioxo-3,4,6,7-tetrahydro pyrido[4,3-d]pyrimidin-l(2H)-yl)phenoxy)-N-methylacetamid (Forbindelse 5); N-cyclopropyl-2-(3-(5-((2-fluor-4-iodophenyl)amino)-6,8-dimethyl-2,4,7-trioxo- 3.4.6.7- tetrahydropyrido[4,3-d]pyrimidin-l(2H)-yl)phenoxy)acetamid (Forbindelse 6); 5-((2-fluor-4-iodophenyl)amino)-6,8-dimethyl-l-(3-(morpholin-4-carbonyl)phenyl) pyrido[4,3-d]pyrimidin-2,4,7(lH,3H,6H)-trion (Forbindelse 7); 1- (3-(l,l-dioxidothiomorpholine-4-carbonyl)phenyl)-5-((2-fluor-4-iodophenyl)amino)-6,8-dimethylpyrido[4,3-d]pyrimidin-2,4,7(lH,3H,6H)-trion (Forbindelse 8); 2- (3-(5-((2-fluor-4-iodophenyl)amino)-6,8-dimethyl-2,4,7-trioxo-3,4,6,7-tetrahydropyrido[4,3-d]pyrimidin-l(2H)-yl)phenyl)-2-methylpropanamid(Forbindelse 9); 2- (3-(5-((2-fluor-4-iodophenyl)amino)-6,8-dimethyl-2,4,7-trioxo-3,4,6,7-tetrahydropyrido[4,3-d]pyrimidin-l(2H)-yl)phenyl)-N,N-dimethylacetamid (Forbindelse 10); N-(l-carbamoylcyclopropyl)-3-(5-((2-fluor-4-iodophenyl)amino)-6,8-dimethyl-2,4,7-trioxo-3,4,6,7-tetrahydropyrido[4,3-d]pyrimidin-l(2H)-yl)benzamid (Forbindelse 12); 3- (5-((2-fluor-4-iodophenyl)amino)-6,8-dimethyl-2,4,7-trioxo-3,4,6,7-tetrahydropyrido[4,3-d]pyrimidin-l(2H)-yl)-N-(tetrahydro-2H-pyran-4-yl)benzamid (Forbindelse 13); 2- (3-(5-((2-fluor-4-iodophenyl)amino)-6,8-dimethyl-2,4,7-trioxo-3,4,6,7-tetrahydropyrido[4,3-d]pyrimidin-l(2H)-yl)phenyl)-2-hydroxyacetamid (Forbindelse 14); 3- (3-(5-((2-fluor-4-iodophenyl)amino)-6,8-dimethyl-2,4,7-trioxo-3,4,6,7-tetrahydropyrido[4,3-d]pyrimidin-l(2H)-yl)phenyl)-N-methylpropanamid (Forbindelse 15); 2-(3-(5-((2-fluor-4-iodophenyl)amino)-6,8-dimethyl-2,4,7-trioxo-3,4,6,7-tetrahydropyrido[4,3-d]pyrimidin-l(2H)-yl)phenoxy)acetamid (Forbindelse 16); 1- (3-(l,l-dioxidothiazolidine-3-carbonyl)phenyl)-5-((2-fluor-4-iodophenyl)amino)-6,8-dimethylpyrido[4,3-d]pyrimidin-2,4,7(lH,3H,6H)-trion (Forbindelse 17); 5-((2-fluor-4-iodophenyl)amino)-l-(3-(4-hydroxypiperidine-l-carbonyl)phenyl)-6,8-dimethylpyrido[4,3-d]pyrimidin-2,4,7(lH,3H,6H)-trion (Forbindelse 18); N-cyclopropyl-3-(3-(5-((2-fluor-4-iodophenyl)amino)-6,8-dimethyl-2,4,7-trioxo- 3.4.6.7- tetrahydropyrido[4,3-d]pyrimidin-l(2H)-yl)phenyl)propanamid (Forbindelse 19); 2- (3-(5-((2-fluor-4-iodophenyl)amino)-6,8-dimethyl-2,4,7-trioxo-3,4,6,7-tetrahydropyrido[4,3-d]pyrimidin-l(2H)-yl)phenoxy)-2-methylpropanamid (Forbindelse 20); 5-((2-fluor-4-iodophenyl)amino)-6,8-dimethyl-l-(3-(4-methylpiperazine-l-carbonyl) phenyl)pyrido[4,3-d]pyrimidin-2,4,7(lH,3H,6H)-trion (Forbindelse 21); 5-((2-fluor-4-iodophenyl)amino)-l-(3-(3-hydroxypyrrolidine-l-carbonyl)phenyl)-6,8-dimethylpyrido[4,3-d]pyrimidin-2,4,7(lH,3H,6H)-trion (Forbindelse 22); 5-((2-fluor-4-iodophenyl)amino)-6,8-dimethyl-l-(3-(piperazin-l-carbonyl)phenyl)pyrido[4,3-d]pyrimidin-2,4,7(lH,3H,6H)-trion (Forbindelse 23); 1- (3-(azetidine-l-carbonyl)phenyl)-3-cyclopropyl-5-((2-fluor-4-iodophenyl)amino)-6,8-dimethylpyrido[4,3-d]pyrimidin-2,4,7(lH,3H,6H)-trion (Forbindelse 24); N-cyclopropyl-2-(3-(3-cyclopropyl-5-((2-fluor-4-iodophenyl)amino)-6,8-dimethyl- 2,4,7-trioxo-3,4/6,7-tetrahydropyrido[4,3-d]pyrimidin-l(2H)-yl)phenoxy)acetamid (Forbindelse 25); 2- (3-(3-cyclopropyl-5-((2-fluor-4-iodophenyl)amino)-6,8-dimethyl-2,4,7-trioxo-3,4/6,7-tetrahydropyrido[4,3-d]pyrimidin-l(2H)-yl)phenyl)acetamid (Forbindelse 26); 3- cyclopropyl-5-((2-fluor-4-iodophenyl)amino)-6,8-dimethyl-l-(3-(pyrrolidin-l-carbonyl)phenyl)pyrido[4,3-d]pyrimidin-2,4,7(lH,3H,6H)-trion (Forbindelse 27); 2-(3-(3-cyclopropyl-5-((2-fluor-4-iodophenyl)amino)-6,8-dimethyl-2,4,7-trioxo-3,4/6,7-tetrahydropyrido[4,3-d]pyrimidin-l(2H)-yl)phenyl)-2-methylpropanamid (Forbindelse 28); 2-(3-(3-cyclopropyl-5-((2-fluor-4-iodophenyl)amino)-6,8-dimethyl-2,4,7-trioxo-3,4/6,7-tetrahydropyrido[4,3-d]pyrimidin-l(2H)-yl)phenyl)-N,N-dimethylacetamid (Forbindelse 29); 2-(3-(3-cyclopropyl-5-((2-fluor-4-iodophenyl)amino)-6,8-dimethyl-2,4,7-trioxo-3,4/6,7-tetrahydropyrido[4,3-d]pyrimidin-l(2H)-yl)phenyl)-N-(oxetan-3-yl)acetamid (Forbindelse 31); 2- (3-(3-cyclopropyl-5-((2-fluor-4-iodophenyl)amino)-6,8-dimethyl-2,4,7-trioxo-3,4/6,7-tetrahydropyrido[4,3-d]pyrimidin-l(2H)-yl)phenyl)-2-hydroxyacetamid (Forbindelse 32); 3- cyclopropyl-5-((2-fluor-4-iodophenyl)amino)-l-(3-(2-(3-hydroxyazetidin-l-yl)-2-oxo ethyl)phenyl)-6,8-dimethylpyrido[4,3-d]pyrimidin-2,4,7(lH,3H,6H)-trion (Forbindelse 33); 3-(3-(3-cyclopropyl-5-((2-fluor-4-iodophenyl)amino)-6,8-dimethyl-2,4,7-trioxo-3,4/6,7-tetrahydropyrido[4,3-d]pyrimidin-l(2H)-yl)phenyl)propanamid (Forbindelse 34); 2- (3-(3-cyclopropyl-5-((2-fluor-4-iodophenyl)amino)-6,8-dimethyl-2,4,7-trioxo-3,4/6,7-tetrahydropyrido[4,3-d]pyrimidin-l(2H)-yl)phenoxy)acetamid (Forbindelse 35); 3- (3-(3-cyclopropyl-5-((2-fluor-4-iodophenyl)amino)-6,8-dimethyl-2,4,7-trioxo-3,4/6,7-tetrahydropyrido[4,3-d]pyrimidin-l(2H)-yl)phenyl)-N-methylpropanamid (Forbindelse 36); N-cyclopropyl-3-(3-cyclopropyl-5-((2-fluor-4-iodophenyl)amino)-6,8-dimethyl-2,4,7-trioxo-3,4/6,7-tetrahydropyrido[4,3-d]pyrimidin-l(2H)-yl)benzamid (Forbindelse 37); 3-cyclopropyl-l-(3-(l,l"dioxidothiazolidine-3-carbonyl)phenyl)-5-((2-fluor-4-iodophenyl)amino)-6,8-dimethylpyrido[4,3-d]pyrimidin-2,4,7(lH,3H,6H)-trion (Forbindelse 38) ; 3-cyclopropyl-1-(3-( l,l-dioxidothiomorpholine-4-carbonyl)phenyl)-5-((2-fluor-4-iodo phenyl)amino)-6,8-dimethylpyrido[4,3-d]pyrimidin-2,4,7(lH,3H,6H)-trion (Forbindelse 39) ; N-cyclopropyl-3-(3-(3-cyclopropyl-5-((2-fluor-4-iodophenyl)amino)-6,8-dimethyl- 2,4,7-trioxo-3,4/6,7-tetrahydropyrido[4,3-d]pyrimidin-l(2H)-yl)phenyl)propanamid (Forbindelse 40); N-cyclopropyl-2-(3-(5-((2-fluor-4-iodophenyl)amino)-3,6,8-trimethyl-2,4,7-trioxo-3,4/6,7-tetrahydropyrido[4,3-d]pyrimidin-l(2H)-yl)phenoxy)acetamid (Forbindelse 41); 2-(3-(5-((2-fluor-4-iodophenyl)amino)-3,6,8-trimethyl-2,4,7-trioxo-3,4,6,7-tetrahydropyrido[4,3-d]pyrimidin-l(2H)-yl)phenyl)acetamid (Forbindelse 42); 2-(3-(5-((2-fluor-4-iodophenyl)amino)-3,6,8-trimethyl-2,4,7-trioxo-3,4,6,7-tetra hydropyrido[4,3-d]pyrimidin-l(2H)-yl)phenyl)-2-methylpropanamid (Forbindelse 43); 2-(3-(5-((2-fluor-4-iodophenyl)amino)-3,6,8-trimethyl-2,4,7-trioxo-3,4,6,7-tetra hydropyrido[4,3-d]pyrimidin-l(2H)-yl)phenyl)-N,N-dimethylacetamid (Forbindelse 44); 2,2-difluor-2-(3-(5-((2-fluor-4-iodophenyl)amino)-3,6,8-trimethyl-2,4,7-trioxo-3,4/6,7-tetrahydropyrido[4,3-d]pyrimidin-l(2H)-yl)phenyl)acetamid (Forbindelse 45); 1- (3-(2-(azetidin-l-yl)-2-oxoethyl)phenyl)-5-((2-fluor-4-iodophenyl)amino)-3,6,8-trimethylpyrido[4,3-d]pyrimidin-2,4,7(lH,3H,6H)-trion (Forbindelse 46); 2- (3-(5-((2-fluor-4-iodophenyl)amino)-3,6,8-trimethyl-2,4,7-trioxo-3,4,6,7-tetra hydropyrido[4,3-d]pyrimidin-l(2H)-yl)phenyl)-2-hydroxyacetamid (Forbindelse 47); 5-((2-fluor-4-iodophenyl)amino)-l-(3-(2-(3-hydroxyazetidin-l-yl)-2-oxoethyl) phenyl)-3,6,8-trimethylpyrido[4,3-d]pyrimidin-2,4,7(lH,3H,6H)-trion (Forbindelse 48); 3- (5-((2-fluor-4-iodophenyl)amino)-3,6,8-trimethyl-2,4,7-trioxo-3,4,6,7-tetra hydropyrido[4,3-d]pyrimidin-l(2H)-yl)-N-(oxetan-3-yl)benzamid (Forbindelse 49); 2- (3-(5-((2-fluor-4-iodophenyl)amino)-3,6,8-trimethyl-2,4,7-trioxo-3,4,6,7-tetra hydropyrido[4,3-d]pyrimidin-l(2H)-yl)phenyl)-N-(oxetan-3-yl)acetamid (Forbindelse 50); 3- (5-((2-fluor-4-iodophenyl)amino)-3,6,8-trimethyl-2,4,7-trioxo-3,4,6,7-tetra hydropyrido[4,3-d]pyrimidin-l(2H)-yl)-N-(tetrahydrofuran-3-yl)benzamid (Forbindelse 51); 3-(5-((2-fluor-4-iodophenyl)amino)-3,6,8-trimethyl-2,4,7-trioxo-3,4,6,7-tetrahydropyrido[4,3-d]pyrimidin-l(2H)-yl)-N-(tetrahydro-2H-pyran-4-yl)benzamid (Forbindelse 52); 3-(5-((2-fluor-4-iodophenyl)amino)-3,6,8-trimethyl-2,4,7-trioxo-3,4,6,7-tetrahydropyrido[4,3-d]pyrimidin-l(2H)-yl)-N-(l-(hydroxymethyl)cyclopropyl) benzamid (Forbindelse 53); N-cyclopropyl-3-(5-((2-fluor-4-iodophenyl)amino)-3,6,8-trimethyl-2,4,7-trioxo- 3.4.6.7- tetrahydropyrido[4,3-d]pyrimidin-l(2H)-yl)benzamid (Forbindelse 54); N-cyclopropyl-3-(5-((2-fluor-4-iodophenyl)amino)-3-(2-hydroxyethyl)-6,8-dimethyl- 2.4.7- trioxo-3,4/6,7-tetrahydropyrido[4,3-d]pyrimidin-l(2H)-yl)benzamid (Forbindelse 55); 1- (3-(azetidine-l-carbonyl)phenyl)-5-((2-fluor-4-iodophenyl)amino)-3,6,8-trimethylpyrido[4,3-d]pyrimidin-2,4,7(lH,3H,6H)-trion (Forbindelse 56); 2- (3-(5-((2-fluor-4-iodophenyl)amino)-3,6,8-trimethyl-2,4,7-trioxo-3,4,6,7-tetrahydropyrido[4,3-d]pyrimidin-l(2H)-yl)phenoxy)acetamid (Forbindelse 57); N-cyclopropyl-2-(3-(5-((2-fluor-4-iodophenyl)amino)-3,6,8-trimethyl-2,4,7-trioxo-3,4/6,7-tetrahydropyrido[4,3-d]pyrimidin-l(2H)-yl)phenyl)acetamid (Forbindelse 58); N-cyclopropyl-2-(3-(3-ethyl-5-((2-fluor-4-iodophenyl)amino)-6,8-dimethyl-2,4,7-trioxo-3,4/6,7-tetrahydropyrido[4,3-d]pyrimidin-l(2H)-yl)phenyl)acetamid (Forbindelse 59); 2- (3-(5-((2-fluor-4-iodophenyl)amino)-3,6,8-trimethyl-2,4,7-trioxo-3,4,6,7-tetrahydropyrido[4,3-d]pyrimidin-l(2H)-yl)phenoxy)-N-methylacetamid (Forbindelse 60); 3- (3-(3-ethyl-5-((2-fluor-4-iodophenyl)amino)-6,8-dimethyl-2,4,7-trioxo-3,4,6,7-tetrahydropyrido[4,3-d]pyrimidin-l(2H)-yl)phenyl)propanamid (Forbindelse 61); N-cyclopropyl-3-(3-ethyl-5-((2-fluor-4-iodophenyl)amino)-6,8-dimethyl-2,4,7-trioxo-3,4/6,7-tetrahydropyrido[4,3-d]pyrimidin-l(2H)-yl)benzamid (Forbindelse 62); 5-((2-fluor-4-iodophenyl)amino)-3,6,8-trimethyl-l-(3-(morpholin-4-carbonyl)phenyl)pyrido[4,3-d]pyrimidin-2,4,7(lH,3H,6H)-trion (Forbindelse 63); l-(3-(l,l"dioxidothiomorpholine-4-carbonyl)phenyl)-5-((2-fluor-4-iodophenyl)amino)-3,6,8-trimethylpyrido[4,3-d]pyrimidin-2,4,7(lH,3H,6H)-trion (Forbindelse 65); 1- (3-(l,l"dioxidothiomorpholine-4-carbonyl)phenyl)-3 -ethyl-5-((2-fluor-4- iodophenyl)amino)-6,8-dimethylpyrido[4,3-d]pyrimidin-2,4,7(lH,3H,6H)-trion (Forbindelse 66); 2- (3-(3-ethyl-5-((2-fluor-4-iodophenyl)amino)-6,8-dimethyl-2,4,7-trioxo-3,4,6,7-tetrahydropyrido[4,3-d]pyrimidin-l(2H)-yl)phenyl)-N,N-dimethylacetamid (Forbindelse 67); 3- (3-(5-((2-fluor-4-iodophenyl)amino)-3,6,8-trimethyl-2,4,7-trioxo-3,4,6,7-tetrahydropyrido[4,3-d]pyrimidin-l(2H)-yl)phenyl)propanamid (Forbindelse 68); N-cyclopropyl-3-(5-((2-fluor-4-iodophenyl)amino)-3-isopropyl-6,8-dimethyl-2,4,7-trioxo-3,4/6,7-tetrahydropyrido[4,3-d]pyrimidin-l(2H)-yl)benzamid (Forbindelse 69); 2-(3-(5-((2-fluor-4-iodophenyl)amino)-6,8-dimethyl-3-(oxetan-3-yl)-2,4,7-trioxo-3,4/6,7-tetrahydropyrido[4,3-d]pyrimidin-l(2H)-yl)phenoxy)acetamid (Forbindelse 71); N-cyclopropyl-3-(3-(difluoromethyl)-5-((2-fluor-4-iodophenyl)amino)-6,8-dimethyl- 2,4,7-trioxo-3,4/6,7-tetrahydropyrido[4,3-d]pyrimidin-l(2H)-yl)benzamid (Forbindelse 72); N-cyclopropyl-3-(3-(2,3-dihydroxypropyl)-5-((2-fluor-4-iodophenyl)amino)-6,8-dimethyl-2,4,7-trioxo-3,4,6,7-tetrahydropyrido[4,3-d]pyrimidin-l(2H)-yl)benzamid (Forbindelse 73); 2-(l-(3-(cyclopropylcarbamoyl)phenyl)-5-((2-fluor-4-iodophenyl)amino)-6,8-dimethyl-2,4,7-trioxo-l,2,6,7-tetrahydropyrido[4,3-d]pyrimidin-3(4H)-yl)eddikesyre (Forbindelse 74); (R) -2-(3-(5-((2-fluor-4-iodophenyl)amino)-3,6,8-trimethyl-2,4,7-trioxo-3,4,6,7-tetrahydropyrido[4,3-d]pyrimidin-l(2H)-yl)phenyl)-2-hydroxyacetamid (Forbindelse 75); (S) -2-(3-(5-((2-fluor-4-iodophenyl)amino)-3,6,8-trimethyl-2,4,7-trioxo-3,4,6,7-tetrahydropyrido[4,3-d]pyrimidin-l(2H)-yl)phenyl)-2-hydroxyacetamid (Forbindelse 76); l-(3-(5-((2-fluor-4-iodophenyl)amino)-6,8-dimethyl-2,4,7-trioxo-3,4,6,7-tetrahydropyrido [4,3-d]pyrimidin-l(2H)-yl)phenyl)cyclopropanecarboxamid (Forbindelse 77); l-(3-(3-cyclopropyl-5-((2-fluor-4-iodophenyl) amino)-6,8-dimethyl-2,4,7-trioxo- 3,4,6,7-tetra hydropyrido[4,3-d]pyrimidin-l(2H)-yl)phenyl)cyclopropan carboxamid (Forbindelse 78); og l-(3-(5-((2-fluor-4-iodophenyl)amino)-3,6,8-trimethyl-2,4,7-trioxo-3,4,6,7-tetrahydro pyrido[4,3-d]pyrimidin-l(2H)-yl)phenyl)cyclopropanecarboxamid (Forbindelse 79).
  10. 10. Farmaceutisk sammensætning omfattende en forbindelse eller et farmaceutisk acceptabelt salt ifølge et hvilket som helst af kravene 1-9 og én eller flere farmaceutisk acceptabelt bærestoffer, fortyndingsmidler eller excipienser.
  11. 11. Forbindelse ifølge formel (I), dens tautomere form, dens stereoisomer eller dets farmaceutisk acceptable salt, ifølge et hvilket som helst af krav 1-9, til anvendelse ved at inhibere MEK-enzymer, hvor forbindelsen foreligger i en mængde tilstrækkelig til at inhibere enzymet.
  12. 12. Forbindelse ifølge formel (I), dens tautomere form, dens stereoisomer eller dets farmaceutisk acceptable salt, ifølge et hvilket som helst af krav 1-9, til anvendelse i behandling af en MEK-medieret lidelse hos et individ, som lider af lidelsen, hvor forbindelsen foreligger i en virkningsfuld mængde.
  13. 13. Forbindelse ifølge formel (I), dens tautomere form, dens stereoisomer eller dets farmaceutisk acceptable salt ifølge et hvilket som helst af krav 1-9, til anvendelse i behandlingen eller forebyggelsen af en proliferativ sygdom eller en inflammatorisk sygdom hos et individ med behov derfor, hvor forbindelsen foreligger i en virkningsfuld mængde.
  14. 14. Forbindelse ifølge formel (I), dens tautomere form, dens stereoisomer eller dets farmaceutisk acceptable salt, ifølge et hvilket som helst af krav 1-9, til anvendelse i at nedbryde, at inhibere væksten af eller at dræbe cancerceller, hvor forbindelsen foreligger i en virkningsfuld mængde.
  15. 15. Forbindelse ifølge formel (I), dens tautomere form, dens stereoisomer eller dets farmaceutisk acceptable salt, ifølge et hvilket som helst af krav 1-9, til anvendelse ved at inhibere tumorstørrelsesforøgelse, at reducere størrelsen af en tumor, at reducere tumorproliferation eller at forebygge tumorproliferation hos et individ med behov derfor, hvor forbindelsen foreligger i en virkningsfuld mængde.
  16. 16. Forbindelse ifølge formel (I), dens tautomere form, dens stereoisomer eller dets farmaceutisk acceptable salt, til anvendelse ifølge krav 13, hvor den proliferative sygdom er cancer, psoriasis, restenose, autoimmun sygdom eller aterosklerose.
  17. 17. Forbindelse ifølge formel (I), dens tautomere form, dens stereoisomer eller dets farmaceutisk acceptable salt, til anvendelse ifølge krav 16, hvor canceren er småcellet eller ikke-småcellet lungekræft.
DK13712929.2T 2012-03-14 2013-03-11 Heterocyclylforbindelser som mek-inhitorer DK2834237T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN288KO2012 2012-03-14
PCT/IB2013/051908 WO2013136249A1 (en) 2012-03-14 2013-03-11 Heterocyclyl compounds as mek inhibitors

Publications (1)

Publication Number Publication Date
DK2834237T3 true DK2834237T3 (da) 2018-08-27

Family

ID=47997632

Family Applications (2)

Application Number Title Priority Date Filing Date
DK13712929.2T DK2834237T3 (da) 2012-03-14 2013-03-11 Heterocyclylforbindelser som mek-inhitorer
DK13711973.1T DK2834236T3 (da) 2012-03-14 2013-03-11 Heterocyclylforbindelser

Family Applications After (1)

Application Number Title Priority Date Filing Date
DK13711973.1T DK2834236T3 (da) 2012-03-14 2013-03-11 Heterocyclylforbindelser

Country Status (35)

Country Link
US (5) US9428499B2 (da)
EP (2) EP2834236B1 (da)
JP (3) JP6431770B2 (da)
KR (4) KR20140138911A (da)
CN (4) CN108383836B (da)
AP (2) AP3834A (da)
AU (4) AU2013234014B2 (da)
BR (1) BR112014022713B1 (da)
CA (2) CA2865167C (da)
CL (2) CL2014002411A1 (da)
CO (2) CO7170131A2 (da)
CR (2) CR20140464A (da)
CU (2) CU24335B1 (da)
DK (2) DK2834237T3 (da)
DO (2) DOP2014000203A (da)
EA (2) EA028232B1 (da)
ES (2) ES2684517T3 (da)
GE (2) GEP201706774B (da)
GT (2) GT201400196A (da)
IL (2) IL234560A (da)
IN (2) IN2014MN01754A (da)
MA (2) MA37400B1 (da)
MX (3) MX355474B (da)
MY (2) MY175950A (da)
NI (2) NI201400107A (da)
NZ (2) NZ629442A (da)
PE (2) PE20141973A1 (da)
PH (2) PH12014502040B1 (da)
PL (1) PL2834237T3 (da)
SG (2) SG11201405007QA (da)
TN (2) TN2014000357A1 (da)
TR (1) TR201811976T4 (da)
UA (2) UA114906C2 (da)
WO (2) WO2013136254A1 (da)
ZA (1) ZA201406186B (da)

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012088266A2 (en) 2010-12-22 2012-06-28 Incyte Corporation Substituted imidazopyridazines and benzimidazoles as inhibitors of fgfr3
IN2014MN01754A (da) 2012-03-14 2015-07-03 Lupin Ltd
LT3495367T (lt) 2012-06-13 2021-02-25 Incyte Holdings Corporation Pakeistieji tricikliniai junginiai, kaip fgfr inhibitoriai
WO2014026125A1 (en) 2012-08-10 2014-02-13 Incyte Corporation Pyrazine derivatives as fgfr inhibitors
US9266892B2 (en) 2012-12-19 2016-02-23 Incyte Holdings Corporation Fused pyrazoles as FGFR inhibitors
LT2986610T (lt) 2013-04-19 2018-04-10 Incyte Holdings Corporation Bicikliniai heterociklai, kaip fgfr inhibitoriai
CN104936945B (zh) 2013-10-25 2017-11-03 上海恒瑞医药有限公司 吡啶酮类衍生物、其制备方法及其在医药上的应用
WO2016009306A1 (en) * 2014-07-15 2016-01-21 Lupin Limited Heterocyclyl compounds as mek inhibitors
WO2016035008A1 (en) * 2014-09-04 2016-03-10 Lupin Limited Pyridopyrimidine derivatives as mek inhibitors
US10851105B2 (en) 2014-10-22 2020-12-01 Incyte Corporation Bicyclic heterocycles as FGFR4 inhibitors
WO2016134294A1 (en) 2015-02-20 2016-08-25 Incyte Corporation Bicyclic heterocycles as fgfr4 inhibitors
MA41551A (fr) 2015-02-20 2017-12-26 Incyte Corp Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr4
SG11201706287PA (en) 2015-02-20 2017-09-28 Incyte Corp Bicyclic heterocycles as fgfr inhibitors
US10898487B2 (en) 2016-12-22 2021-01-26 Boehringer Ingelheim International Gmbh Benzylamino substituted quinazolines and derivatives as SOS1 inhibitors
AR111960A1 (es) 2017-05-26 2019-09-04 Incyte Corp Formas cristalinas de un inhibidor de fgfr y procesos para su preparación
ES2944306T3 (es) * 2017-12-21 2023-06-20 Boehringer Ingelheim Int Piridopirimidinonas sustituidas por bencilamino y derivados como inhibidores de SOS1
ES3061844T3 (en) 2018-05-04 2026-04-07 Incyte Corp Salts of an fgfr inhibitor
MX2020011718A (es) 2018-05-04 2021-02-15 Incyte Corp Formas solidas de un inhibidor de receptores del factor de crecimiento de fibroblastos (fgfr) y procesos para prepararlas.
US11628162B2 (en) 2019-03-08 2023-04-18 Incyte Corporation Methods of treating cancer with an FGFR inhibitor
EP3942045A1 (en) 2019-03-21 2022-01-26 Onxeo A dbait molecule in combination with kinase inhibitor for the treatment of cancer
PH12021553105A1 (en) 2019-06-19 2022-07-25 Boehringer Ingelheim Int Anticancer combination therapy
US11591329B2 (en) 2019-07-09 2023-02-28 Incyte Corporation Bicyclic heterocycles as FGFR inhibitors
CN114502169A (zh) * 2019-07-30 2022-05-13 埃德文斯公司 用于治疗中风的mek抑制剂
EP3797899A1 (de) 2019-09-27 2021-03-31 Primetals Technologies Austria GmbH Vorrichtung und verfahren zum erkennen von einer bewegung eines körpers in einer industrieanlage
US12122767B2 (en) 2019-10-01 2024-10-22 Incyte Corporation Bicyclic heterocycles as FGFR inhibitors
TWI891666B (zh) 2019-10-14 2025-08-01 美商英塞特公司 作為ｆｇｆｒ抑制劑之雙環雜環
US11566028B2 (en) 2019-10-16 2023-01-31 Incyte Corporation Bicyclic heterocycles as FGFR inhibitors
EP4054579A1 (en) 2019-11-08 2022-09-14 Institut National de la Santé et de la Recherche Médicale (INSERM) Methods for the treatment of cancers that have acquired resistance to kinase inhibitors
WO2021113462A1 (en) 2019-12-04 2021-06-10 Incyte Corporation Derivatives of an fgfr inhibitor
CA3163875A1 (en) 2019-12-04 2021-06-10 Incyte Corporation Tricyclic heterocycles as fgfr inhibitors
US12012409B2 (en) 2020-01-15 2024-06-18 Incyte Corporation Bicyclic heterocycles as FGFR inhibitors
WO2021148581A1 (en) 2020-01-22 2021-07-29 Onxeo Novel dbait molecule and its use
AU2021285032A1 (en) 2020-06-02 2022-12-08 Boehringer Ingelheim International Gmbh Annulated 2-amino-3-cyano thiophenes and derivatives for the treatment of cancer
TWI825637B (zh) 2021-03-31 2023-12-11 美商輝瑞股份有限公司 啶－１，６（２ｈ，７ｈ）－二酮
US20240238294A1 (en) 2021-04-09 2024-07-18 Boehringer Ingelheim International Gmbh Anticancer therapy
TW202304459A (zh) 2021-04-12 2023-02-01 美商英塞特公司 包含ｆｇｆｒ抑制劑及ｎｅｃｔｉｎ－４靶向劑之組合療法
WO2022221866A1 (en) * 2021-04-16 2022-10-20 Ikena Oncology, Inc. Mek inhibitors and uses thereof
WO2022251193A1 (en) 2021-05-27 2022-12-01 Mirati Therapeutics, Inc. Combination therapies
JP2024522189A (ja) 2021-06-09 2024-06-11 インサイト・コーポレイション Ｆｇｆｒ阻害剤としての三環式ヘテロ環
EP4352060A1 (en) 2021-06-09 2024-04-17 Incyte Corporation Tricyclic heterocycles as fgfr inhibitors
CN119013272A (zh) 2021-12-01 2024-11-22 勃林格殷格翰国际有限公司 用于治疗癌症的环状2-氨基-3-氰基噻吩及其衍生物
CR20240233A (es) 2021-12-01 2024-07-17 Univ Vanderbilt Tiofenos 2-amino-3-ciano anulados y derivados para el tratamiento del cáncer
WO2023099623A1 (en) 2021-12-01 2023-06-08 Boehringer Ingelheim International Gmbh Annulated 2-amino-3-cyano thiophenes and derivatives for the treatment of cancer
EP4441051A1 (en) 2021-12-01 2024-10-09 Boehringer Ingelheim International GmbH Kras degrading compounds comprising annulated 2-amino-3-cyano thiophenes
EP4441056A1 (en) 2021-12-01 2024-10-09 Boehringer Ingelheim International GmbH Annulated 2-amino-3-cyano thiophenes and derivatives for the treatment of cancer
CN114456166B (zh) * 2022-03-30 2023-06-16 沈阳药科大学 5-取代氨基-3-甲基吡啶并[2,3-d]嘧啶类化合物及其制备与应用
CN114573582B (zh) * 2022-03-30 2023-06-16 沈阳药科大学 1,2,3,4-四氢吡啶并[2,3-d]嘧啶类化合物及其制备方法和应用
CN114573581B (zh) * 2022-03-30 2023-09-01 沈阳药科大学 5-取代氨基-1,3-二取代苯基吡啶并[2,3-d]嘧啶类化合物及其制备与应用
CN114605408B (zh) * 2022-03-30 2023-06-16 沈阳药科大学 5-羟基-1,3-二取代苯基吡啶并[2,3-d]嘧啶类化合物及其制法和应用
KR20250040894A (ko) 2022-05-25 2025-03-25 이케나 온콜로지, 인코포레이티드 Mek 억제제 및 이의 용도
JP7854973B2 (ja) * 2022-09-26 2026-05-07 ファイザー・インク Ｍｅｋ阻害剤としての３，４－ジヒドロ－２，７－ナフチリジン－１，６（２ｈ，７ｈ）－ジオン
US20250019385A1 (en) 2023-05-30 2025-01-16 Boehringer Ingelheim International Gmbh Spirocyclic annulated 2-amino-3-cyano thiophenes and derivatives for the treatment of cancer
WO2025073765A1 (en) 2023-10-03 2025-04-10 Institut National de la Santé et de la Recherche Médicale Methods of prognosis and treatment of patients suffering from melanoma

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4235871A (en) 1978-02-24 1980-11-25 Papahadjopoulos Demetrios P Method of encapsulating biologically active materials in lipid vesicles
US4501728A (en) 1983-01-06 1985-02-26 Technology Unlimited, Inc. Masking of liposomes from RES recognition
US5019369A (en) 1984-10-22 1991-05-28 Vestar, Inc. Method of targeting tumors in humans
US4837028A (en) 1986-12-24 1989-06-06 Liposome Technology, Inc. Liposomes with enhanced circulation time
UA72612C2 (en) * 2000-07-06 2005-03-15 Pyrido[2.3-d]pyrimidine and pyrimido[4.5-d]pyrimidine nucleoside analogues, prodrugs and method for inhibiting growth of neoplastic cells
US6825180B2 (en) * 2001-05-18 2004-11-30 Cell Therapeutics, Inc. Pyridopyrimidine compounds and their uses
GB0129099D0 (en) 2001-12-05 2002-01-23 Astrazeneca Ab Chemical compounds
ATE314370T1 (de) * 2002-01-22 2006-01-15 Warner Lambert Co 2-(pyridin-2-ylamino)-pyrido(2,3-d)pyrimidin-7- one
US7235537B2 (en) 2002-03-13 2007-06-26 Array Biopharma, Inc. N3 alkylated benzimidazole derivatives as MEK inhibitors
NZ547481A (en) 2003-11-19 2009-12-24 Array Biopharma Inc Heterocyclic inhibitors of mek and methods of use thereof
US7378423B2 (en) * 2004-06-11 2008-05-27 Japan Tobacco Inc. Pyrimidine compound and medical use thereof
PT2298768E (pt) * 2004-06-11 2012-12-05 Japan Tobacco Inc Derivados de 5-amino-2,4,7-trioxo-3,4,7,8-tetra-hidro-2hpirido[ 2,3-d]pirimidina e compostos relacionados para o tratamento do cancro
CN102458580A (zh) 2009-04-21 2012-05-16 诺瓦提斯公司 作为mek抑制剂的杂环化合物
IN2014MN01754A (da) * 2012-03-14 2015-07-03 Lupin Ltd

Also Published As

Publication number Publication date
EP2834236B1 (en) 2019-05-22
PH12014502041A1 (en) 2014-11-24
CA2865167A1 (en) 2013-09-19
KR20140138910A (ko) 2014-12-04
US9827247B2 (en) 2017-11-28
KR20190100472A (ko) 2019-08-28
NZ629432A (en) 2017-01-27
AP3859A (en) 2016-10-31
JP2015509975A (ja) 2015-04-02
AU2017200493A1 (en) 2017-02-16
PL2834237T3 (pl) 2018-11-30
BR112014022713B1 (pt) 2021-09-08
US20150299186A1 (en) 2015-10-22
MY175950A (en) 2020-07-16
TN2014000356A1 (en) 2015-12-21
JP6431770B2 (ja) 2018-11-28
EP2834237A1 (en) 2015-02-11
PH12014502041B1 (en) 2014-11-24
CA2865164A1 (en) 2013-09-19
US20150133424A1 (en) 2015-05-14
US9573944B2 (en) 2017-02-21
CO7160029A2 (es) 2015-01-15
CU24335B1 (es) 2018-04-03
AU2018202568B2 (en) 2019-05-09
US9555035B2 (en) 2017-01-31
CR20140464A (es) 2014-11-28
TR201811976T4 (tr) 2018-09-21
AP2014008009A0 (en) 2014-10-31
US20170112840A1 (en) 2017-04-27
CA2865164C (en) 2021-06-08
SG11201405006PA (en) 2014-10-30
KR20140138911A (ko) 2014-12-04
AU2018202568A1 (en) 2018-05-10
CA2865167C (en) 2019-08-06
BR112014022713A2 (da) 2017-06-20
CU20140109A7 (es) 2014-11-27
MA37400B1 (fr) 2019-11-29
ES2684517T3 (es) 2018-10-03
WO2013136249A1 (en) 2013-09-19
PH12014502040A1 (en) 2014-11-24
NZ629442A (en) 2016-12-23
US20160331753A1 (en) 2016-11-17
NI201400107A (es) 2014-11-26
CU24272B1 (es) 2017-08-08
NI201400108A (es) 2014-11-28
US20170101408A1 (en) 2017-04-13
MY174188A (en) 2020-03-12
JP6093384B2 (ja) 2017-03-08
GT201400195A (es) 2017-11-09
PH12014502040B1 (en) 2014-11-24
CU20140110A7 (es) 2014-11-27
SG11201405007QA (en) 2014-10-30
CN107698585A (zh) 2018-02-16
EA028232B1 (ru) 2017-10-31
KR102240101B1 (ko) 2021-04-14
AP2014008008A0 (en) 2014-10-31
WO2013136254A1 (en) 2013-09-19
MX355474B (es) 2018-04-16
CR20140463A (es) 2014-11-28
AP3834A (en) 2016-09-30
DK2834236T3 (da) 2019-08-26
DOP2014000204A (es) 2015-02-15
PE20141974A1 (es) 2014-12-12
CN108383836B (zh) 2021-11-12
EP2834237B1 (en) 2018-06-06
AU2017200493B2 (en) 2018-03-29
AU2013234009B2 (en) 2016-10-27
GEP201706671B (en) 2017-05-25
PE20141973A1 (es) 2014-12-12
HK1206020A1 (en) 2015-12-31
CN108383836A (zh) 2018-08-10
MX2014010925A (es) 2015-04-10
GEP201706774B (en) 2017-11-27
CL2014002411A1 (es) 2015-04-06
MA37405A1 (fr) 2016-03-31
US9969731B2 (en) 2018-05-15
AU2013234014A1 (en) 2014-09-25
KR102241111B1 (ko) 2021-04-15
MX355526B (es) 2018-04-20
UA114907C2 (uk) 2017-08-28
IL234560A (en) 2017-06-29
DOP2014000203A (es) 2015-02-15
UA114906C2 (uk) 2017-08-28
AU2013234014B2 (en) 2017-02-02
US9428499B2 (en) 2016-08-30
JP6630771B2 (ja) 2020-01-15
CN104271577A (zh) 2015-01-07
JP2015514056A (ja) 2015-05-18
HK1202538A1 (en) 2015-10-02
IL234559A (en) 2017-06-29
EA201491671A1 (ru) 2014-12-30
KR20190073597A (ko) 2019-06-26
MX366426B (es) 2019-07-08
ES2741896T3 (es) 2020-02-12
CO7170131A2 (es) 2015-01-28
EA029768B1 (ru) 2018-05-31
JP2018115215A (ja) 2018-07-26
GT201400196A (es) 2017-09-28
CL2014002412A1 (es) 2015-03-06
IN2014MN01755A (da) 2015-07-03
IN2014MN01754A (da) 2015-07-03
TN2014000357A1 (en) 2015-12-21
AU2013234009A1 (en) 2014-09-25
EP2834236A1 (en) 2015-02-11
MA37400A1 (fr) 2016-05-31
EA201491672A1 (ru) 2014-12-30
CN104203947A (zh) 2014-12-10
ZA201406186B (en) 2016-06-29
MX2014010928A (es) 2015-04-10

Similar Documents

Publication Publication Date Title
AU2018202568B2 (en) Heterocyclyl compounds as MEK inhibitors
HK1202538B (en) Heterocyclyl compounds as mek inhibitors
OA17133A (en) Heterocyclyl compounds as MEK inhibitors
HK1206020B (en) Heterocyclyl compounds
OA17318A (en) Heterocyclyl Compounds.